Stay updated on Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial

Sign up to get notified when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T04:30:04.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page has undergone significant changes, including the removal of detailed information about a Phase 3 study on Hepatocellular Carcinoma (HCC) and the revision number has been updated from v2.14.4 to v2.15.0.
    Difference
    12%
    Check dated 2025-04-16T14:32:53.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated to version v2.14.4, replacing the previous version v2.14.3. Additionally, a certification or extension that was first posted on July 5, 2023, has been removed.
    Difference
    0.2%
    Check dated 2025-04-09T09:20:03.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T23:12:27.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1.0%
    Check dated 2025-02-24T20:30:13.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1.0%
    Check dated 2025-02-10T09:41:23.000Z thumbnail image

Stay in the know with updates to Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.